AIDS-related Mycobacterium kansasii infection with initial resistance to clarithromycin

Diagnostic Microbiology and Infectious Disease

Volumn 31, Issue 2, 1998, Pages 369-371

  Burman, William J ^a,b   Stone, Barbara L ^a   Brown, Barbara A ^c   Wallace Jr , Richard J ^c   Böttger, Erik C ^d  

^a DENVER HEALTH MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

^d HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CLARITHROMYCIN; ETHAMBUTOL; ISONIAZID; LAMIVUDINE; OFLOXACIN; PROTEINASE INHIBITOR; RIFABUTIN; RIFAMPICIN; RNA 23S; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATION; CASE REPORT; HUMAN; HUMAN TISSUE; MALE; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIOSIS; MYCOBACTERIUM AVIUM; MYCOBACTERIUM KANSASII; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RNA GENE; SINUSITIS;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DRUG RESISTANCE, MICROBIAL; HUMANS; MYCOBACTERIUM INFECTIONS, ATYPICAL; MYCOBACTERIUM KANSASII;

EID: 0031801609     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(98)00013-3     Document Type: Article

References (22)

1. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am Rev Respir Dis. 142:1990;940-953.
2. Brown B.A., Wallace R.J. Jr, Onyi G.O. Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined using a broth microdilution MIC system. Antimicrob Agents Chemother. 36:1992;1987-1990.
3. Carpenter C.C.J., Fischl M.A., Hammer S.M., et al. Antiretroviral therapy for HIV infection in 1997 updated recommendations of the International AIDS Society - USA panel . JAMA. 277:1997;1962-1969.
4. Chaisson R.E., Benson C.A., Dube M.P., Heifets L.B., Korvick J.A., Elkin S., Smith T., Craft J.C., Sattler F.R. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease randomized, double-blind, dose-ranging study in patients with AIDS . Ann Intern Med. 121:1994;905-911.
5. Dautzenberg B., Truffot C., Legris S., Meyohas M.C., Berlie H.C., Mercat A., Chevret S., Grosset J. Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome a controlled clinical trial . Am Rev Respir Dis. 144:1991;564-569.
6. Dube M.P., Sattler F.R., Torriani F.J., See D., Havlir D.V., Kemper C.A., Dezfuli M.G., Bozzette S.A., Leedom J.M., Tilles J.G., McCutchan J.A. A randomized evaluation of ethambutol for prevention of relapse and drug resistance during treatment of Mycobacterium avium complex bacteremia with clarithromycin-based combination therapy. J Infect Dis. 176:1997;1225-1232.
7. Godofsky E.W., Zinreich J., Armstrong M., Leslie J.M., Weikel C.S. Sinusitis in HIV-infected patients a clinical and radiographic review . Am J Med. 93:1992;163-169.
8. Goudardi C, LeBrun L, Doucet-Populaire F, Vincent V, Nordmann P, Delfraissy JF (1997) Clarithromycin-resistant Mycobacterium avium (MAC) strain in a clarithromycin naive AIDS patient (abstr). 4th Conference on Retroviruses and Opportunistic Infections, Washington, DC.
9. Hammer J, Jarboe E, Stone B, Burman W, Reves R (1997) The utility of clarithromycin disk-susceptibility testing in the management of HIV-associated disseminated M. avium complex infection (abstr). Washington, DC: 4th Conference on Retroviruses and Opportunistic Infections.
10. Havlir D.V., Dube M.P., Sattler F.R., et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N Engl J Med. 335:1996;392-398.
11. Jarboe E, Stone BL, Burman WJ, Wallace RJ Jr, Brown BA, Reves RR, Wilson ML (1998) Evaluation of a disk diffusion method for determining the susceptibility of Mycobacterium avium to clarithromycin Diagn Microbiol Infect Dis. In press.
12. Kerr B, Lee C, Yuen G, et al. (1997) Overview of in-vitro and in-vivo drug interaction studies of nelfinavir mesylate, a new HIV-1 protease inhibitor (abstr). 4th Conference on Retroviruses and Opportunistic Infections, Washington, DC.
13. Meier A., Kirschner P., Springer B., Steingrube V.A., Brown B.A., Wallace R.J. Jr, Bottger E.C. Identification of mutations of 23 rRNA gene of clarithromycin-resistant. Mycobacterium intracellulare. Antimicrob Agents Chemother. 38:1994;381-384.
14. Naguib M.T., Byers J.M., Slater L.N. Paranasal sinus infection due to atypical mycobacteria in two patients with AIDS. Clin Infect Dis. 19:1994;789-791.
15. Pierce M., Crampton S., Henry D., et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med. 335:1996;384-391.
16. Shafran S.D., Singer J., Zarowny D.P., et al. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin . N Engl J Med. 335:1996;377-383.
17. Sommers H.M., Good R.C. Mycobacterium. Balows A., Hausler W.J.J., Shadomy J.H. Manual of Clinical Microbiology. 1985;216-248 American Society for Microbiology, Washington, DC.
18. Tucker R.M., Denning D.W., Hanson L.H., Rinaldi M.G., Graybill J.R., Sharkey P.K., Pappagianis D., Stevens D.A. Interaction of azoles with rifampin, phenytoin, and carbamazepine in vitro and clinical observations . Clin Infect Dis. 14:1992;165-174.
19. Wallace R.J. Jr, Brown B.A., Griffith D.E., Girard W.M., Murphy D.T., Onyi G.O., Steingrube V.A., Mazurek G.H. Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex disease. Am Rev Respir Crit Care Med. 149:1994;1335-1341.
20. Wallace R.J. Jr, Dunbar D., Brown B.A., Onyi G., Dunlap R., Ahn C.H., Murphy D.T. Rifampin-resistant Mycobacterium kansasii. Clin Infect Dis. 18:1994;736-743.
21. Wallace RJ Jr, Meier A, Brown BA, Zhang Y, Sander P, Onyi GO, Bottger EC (1996) Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus. Antimicrob Agents Chemother 40:1676-1681.
22. Witzig R.S., Fanzblau S.G. Susceptibility of Mycobacterium kansasii to ofloxacin, sparfloxacin, clarithromycin, azithromycin, and fusidic acid. Antimicrob Agents Chemother. 37:1993;1997-1999.